Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant envafolimab plus chemotherapy for locally advanced head and neck squamous cell carcinoma
ChiCTR2500100348Phase 4Recruiting
- Sponsor
- Peking University School and Hospital of Stomatology
- Start
- Apr 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of envafolimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Peking University School and Hospital of Stomatology. Primary endpoint: Major pathological response. Started Apr 2025; status: recruiting.
02
Drugs
envafolimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500100348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100348.